Division of Cardiology, Department of Medicine, Cardiac Arrhythmia Center, Montefiore-Einstein Center for Heart and Vascular Care, Albert Einstein College of Medicine, Bronx, New York, USA.
St. David's Medical Center, Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.
J Cardiovasc Electrophysiol. 2021 Jul;32(7):1822-1832. doi: 10.1111/jce.15036. Epub 2021 May 27.
Empirical pulmonary vein isolation (PVI) remains the cornerstone for catheter ablation of atrial fibrillation (AF). Various ablation strategies and modalities are continually tested with the aim of improving ablation outcomes. Although focal impulse and rotor modulation (FIRM)-guided ablation is currently used as an adjunct to PVI, evidence supporting this strategy is conflicting. We sought to examine whether the utilization of FIRM-guided ablation with or without PVI is associated with a decrease in all-atrial arrhythmia recurrence as compared to PVI alone.
A systematic review of PubMed, Cochrane, and Embase was performed for head-to-head study designs comparing outcomes of patients who underwent FIRM-guided ablation with or without PVI to those who underwent PVI alone. The primary efficacy endpoint was all-atrial arrhythmia recurrence. The secondary endpoints were complications rates and procedural characteristics.
Overall, six studies comprising 674 patients undergoing either FIRM-guided ablation ± PVI versus PVI were included (mean age 63.4 ± 9.2, male 74%, 9% paroxysmal AF, 91% nonparoxysmal AF). After a mean follow-up of 18.8 months, FIRM-guided ablation with or without PVI was not associated with improvement in all-atrial arrhythmia recurrence rate compared to PVI alone (43.4% vs. 45.9%, risk ratio [RR]: 1.06; 95% confidence interval [CI]: 0.77-1.47; p = .70). No statistically significant difference was noted in complication rates between the two groups (RR: 1.66; 95% CI: 0.08-34.54; p = .74).
In this meta-analysis of head-to-head comparison studies, FIRM-guided ablation with or without PVI did not provide any benefit in improving all-atrial arrhythmia recurrence at follow-up when compared to PVI alone.
经验性肺静脉隔离(PVI)仍然是心房颤动(AF)导管消融的基石。各种消融策略和方式不断被测试,目的是改善消融效果。虽然目前将焦点冲动和转子调制(FIRM)引导消融用作 PVI 的辅助手段,但支持这种策略的证据存在冲突。我们试图研究与单独进行 PVI 相比,使用或不使用 FIRM 引导消融是否与所有心房心律失常的复发减少相关。
对 PubMed、Cochrane 和 Embase 进行了系统评价,以对头对头研究设计进行了比较,这些研究设计比较了接受 FIRM 引导消融加或不加 PVI 的患者与仅接受 PVI 的患者的结局。主要疗效终点是所有心房心律失常的复发。次要终点是并发症发生率和程序特征。
总体而言,纳入了 6 项研究,共纳入 674 例接受 FIRM 引导消融加或不加 PVI 与单独 PVI 的患者(平均年龄 63.4±9.2 岁,男性 74%,9%为阵发性 AF,91%为非阵发性 AF)。在平均 18.8 个月的随访后,与单独 PVI 相比,加用或不加用 FIRM 引导消融并不能改善所有心房心律失常的复发率(43.4% vs. 45.9%,风险比 [RR]:1.06;95%置信区间 [CI]:0.77-1.47;p=0.70)。两组之间的并发症发生率无统计学差异(RR:1.66;95%CI:0.08-34.54;p=0.74)。
在这项头对头比较研究的荟萃分析中,与单独进行 PVI 相比,加用或不加用 FIRM 引导消融并不能在随访时改善所有心房心律失常的复发。